Stock CTLT CATALENT, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Catalent, Inc.

Equities

CTLT

US1488061029

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:01 2024-04-26 pm EDT 		5-day change 1st Jan Change
55.92 USD +0.22% Intraday chart for Catalent, Inc. +0.79% +24.46%
Apr. 12 Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target is $48 MT
Apr. 08 Sector Update: Health Care Stocks Decline Late Afternoon MT

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 7,899 11,931 18,417 19,228 7,817 10,120 - -
Enterprise Value (EV) 1 10,513 13,996 20,691 22,892 12,386 14,859 14,516 14,382
P/E ratio 60.2 x 64.3 x 34.8 x 37.8 x -33.6 x -12.5 x 128 x 47.3 x
Yield - - - - - - - -
Capitalization / Revenue 3.14 x 3.86 x 4.61 x 3.98 x 1.83 x 2.3 x 2.17 x 2.04 x
EV / Revenue 4.18 x 4.52 x 5.18 x 4.74 x 2.9 x 3.38 x 3.12 x 2.89 x
EV / EBITDA 17.5 x 18.6 x 20.3 x 17.8 x 17.3 x 20.7 x 15.8 x 13.6 x
EV / FCF 355 x -549 x -81.8 x -104 x -38.5 x -91.3 x 94.5 x 77 x
FCF Yield 0.28% -0.18% -1.22% -0.97% -2.6% -1.1% 1.06% 1.3%
Price to Book 4.65 x 4.12 x 4.71 x 4.01 x 1.69 x 2.72 x 2.52 x 2.36 x
Nbr of stocks (in thousands) 145,715 162,770 170,342 179,213 180,272 180,974 - -
Reference price 2 54.21 73.30 108.1 107.3 43.36 55.92 55.92 55.92
Announcement Date 8/27/19 8/31/20 8/30/21 8/29/22 8/29/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,518 3,094 3,998 4,828 4,276 4,398 4,656 4,973
EBITDA 1 599.6 750.9 1,020 1,285 714 716.9 921.1 1,054
EBIT 1 273.9 586 824.3 1,030 428 380.6 592.7 710.9
Operating Margin 10.88% 18.94% 20.62% 21.33% 10.01% 8.65% 12.73% 14.29%
Earnings before Tax (EBT) 1 160.3 260.4 715 605 -315 -825.5 117.3 305.4
Net income 1 137.4 220.7 529 503 -232 -815.8 78.39 217.4
Net margin 5.46% 7.13% 13.23% 10.42% -5.43% -18.55% 1.68% 4.37%
EPS 2 0.9000 1.140 3.110 2.840 -1.290 -4.482 0.4352 1.182
Free Cash Flow 1 29.6 -25.5 -253 -221 -322 -162.8 153.6 186.7
FCF margin 1.18% -0.82% -6.33% -4.58% -7.53% -3.7% 3.3% 3.75%
FCF Conversion (EBITDA) 4.94% - - - - - 16.68% 17.72%
FCF Conversion (Net income) 21.54% - - - - - 195.93% 85.9%
Dividend per Share 2 - - - - - - - -
Announcement Date 8/27/19 8/31/20 8/30/21 8/29/22 8/29/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3
Net sales 1 1,025 1,217 1,273 1,313 1,022 1,149 1,037 1,068 982 1,032 1,123 1,257 1,021 1,067 1,186
EBITDA 1 252 310 339 384 187 283 105 139 115 124 194.3 283.4 163.8 196.1 242.9
EBIT 1 194 246 273 317 121 214 33 60 37 36 106.1 198.1 103.6 114.1 159.4
Operating Margin 18.93% 20.21% 21.45% 24.14% 11.84% 18.62% 3.18% 5.62% 3.77% 3.49% 9.45% 15.76% 10.15% 10.69% 13.45%
Earnings before Tax (EBT) 1 103 115 176 211 3 114 -282 -150 -806 -181 16.3 88.13 -59 4 53
Net income 1 84 93 141 188 - 81 -227 -86 -715 -204 -63.51 32.2 -34 -4.3 29.35
Net margin 8.2% 7.64% 11.08% 14.32% - 7.05% -21.89% -8.05% -72.81% -19.77% -5.65% 2.56% -3.33% -0.4% 2.48%
EPS 2 0.4900 0.5200 0.7800 1.040 - 0.4400 -1.260 -0.4800 -3.940 -1.120 -0.1639 0.2348 -0.1850 -0.0250 0.1600
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/2/21 2/1/22 5/3/22 8/29/22 11/1/22 2/7/23 6/12/23 8/29/23 11/15/23 2/9/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 2,614 2,065 2,274 3,664 4,569 4,739 4,396 4,262
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 4.359 x 2.75 x 2.229 x 2.851 x 6.399 x 6.61 x 4.772 x 4.044 x
Free Cash Flow 1 29.6 -25.5 -253 -221 -322 -163 154 187
ROE (net income / shareholders' equity) 15.7% 12.1% 15.5% 15.9% 15.6% 2.31% 6.67% 8.58%
ROA (Net income/ Total Assets) 4.94% 3.16% 6.26% 7.07% 6.74% 0.78% 2.55% 3.38%
Assets 1 2,779 6,980 8,445 7,110 -3,444 -104,116 3,073 6,440
Book Value Per Share 2 11.70 17.80 23.00 26.80 25.60 20.60 22.20 23.70
Cash Flow per Share 2 1.700 2.890 2.550 2.470 1.440 2.590 4.180 3.600
Capex 1 218 466 686 660 583 398 430 485
Capex / Sales 8.66% 15.05% 17.16% 13.67% 13.63% 9.05% 9.24% 9.76%
Announcement Date 8/27/19 8/31/20 8/30/21 8/29/22 8/29/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Catalent, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
55.92 USD
Average target price
63.5 USD
Spread / Average Target
+13.56%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CATALENT, INC. Stock Catalent, Inc.
+24.46% 10.12B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CTLT Stock
  4. Financials Catalent, Inc.